Lamisil
This medication is indicated to manage fungal skin and nail infections and developed to target the underlying fungal growth.
Strengths: 250mg
Where to Check Availability
Medicine details
- Therapeutic class
Antifungal
- Pharmacological class
Allylamine
- Contraindications
hypersensitivity to terbinafine; acute or chronic liver disease
- Minor side effects
nausea; abdominal pain; diarrhoea; headache; rash
- Moderate side effects
elevated liver enzymes; dysgeusia
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Novartis
- Onset Time
2–4 weeks
- Duration
6–12 weeks
- Storage instructions
Store below 25°C in the original blister pack.
- Drug interactions
Rifampicin; Cimetidine; Warfarin
- Age restrictions
Not generally recommended for children under specific weight thresholds.
Precautions and warnings
monitor liver function regularly; discontinue use if persistent nausea or jaundice occurs
Serious side effects
hepatotoxicity — requires immediate medical attention; neutropenia — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
This medication is indicated to manage fungal skin and nail infections and developed to target the underlying fungal growth.
Mechanism of action
Terbinafine inhibits the enzyme squalene epoxidase in the fungal cell wall. This action prevents the synthesis of ergosterol, a vital component of the fungal cell membrane, resulting in an accumulation of squalene, which causes cell death in the fungus.
Pregnancy and breastfeeding
Pregnancy: use only if clearly necessary. Breastfeeding: should be avoided as terbinafine is excreted in breast milk.
Lamisil
This medication is indicated to manage fungal skin and nail infections and developed to target the underlying fungal growth.
Editorial Notes
- Active ingredient(s): Terbinafine
- Listed indication(s): Tinea Pedis, Tinea Cruris, Tinea Corporis, Onychomycosis
Available option
- 30 tablets - 250 mg93-250-mg-3335